What oral estradiol dose per day is equivalent to a 0.1 mg (100 µg) transdermal estradiol patch?

Oral Estradiol Dose Equivalent to 0.1 mg Transdermal Patch

A 0.1 mg (100 µg) transdermal estradiol patch does not have a simple 1:1 oral equivalent due to fundamental pharmacokinetic differences, but oral estradiol 2 mg daily is commonly used as a comparable starting dose in clinical practice, though it produces markedly different hormone profiles.

Key Pharmacokinetic Differences

The Endocrine Society guidelines explicitly note that oral micronized estradiol results in up to 5-fold higher circulating estrone levels and 10- to 20-fold higher estrone sulfate levels compared to transdermal estradiol at comparable or even higher doses 1. This occurs because:

• First-pass hepatic metabolism: Oral estradiol undergoes extensive liver metabolism before reaching systemic circulation, converting much of it to estrone and estrone sulfate
• Transdermal bypass: Patches deliver estradiol directly into circulation, avoiding this hepatic conversion

Research confirms these dramatic differences—oral administration produces E1/E2 ratios of 9.28 compared to just 2.22 for transdermal routes 2. Another study showed oral estradiol creates large concentration pulses (fluctuation = 3.68) with average concentrations 12-fold higher than transdermal patches, while estrone levels were 9.4-fold higher 3.

Clinical Dosing Considerations

Standard Dose Comparisons

While no exact equivalence exists, clinical practice patterns suggest:

• Transdermal 100 µg patch is frequently prescribed as a higher starting dose for younger women with surgical menopause or premature ovarian insufficiency 1
• Oral estradiol 2 mg is a commonly available tablet strength 4 and represents a standard oral dose
• Oral estradiol 0.5 mg was shown effective for bone protection in clinical trials 5, demonstrating that lower oral doses can achieve therapeutic effects

Important Caveats

The biological effects of the dramatically elevated estrone and estrone sulfate from oral administration remain unknown 1. This is a critical knowledge gap.

Transdermal therapy is explicitly preferable for women with:

• VTE risk (supported by meta-analysis) 1
• Hypertension
• Hypertriglyceridemia
• Obesity or metabolic syndrome
• Diabetes
• History of gallbladder disease

This is because transdermal estradiol avoids the hepatic first-pass effect that increases SHBG, thyroid-binding globulin, cortisol-binding globulin, triglycerides, and inflammatory markers like C-reactive protein 1.

Practical Clinical Approach

Rather than attempting direct dose conversion, the guidelines emphasize using the lowest effective dose with upward titration based on clinical response 1.

• Clinicians typically do not measure estradiol levels to monitor therapy except when symptoms fail to improve with escalating doses, particularly after changing from oral to transdermal administration 1
• The choice between routes should prioritize the patient's cardiovascular and metabolic risk profile, not dose equivalence
• No head-to-head RCTs with clinical outcomes compare transdermal with oral therapies 1

Bottom Line

If switching from a 100 µg transdermal patch to oral therapy, starting with oral estradiol 2 mg daily is reasonable, but recognize this will produce vastly different hormone profiles with unknown clinical significance. Whenever possible, maintain transdermal therapy rather than converting to oral, especially in women with any cardiovascular or metabolic risk factors.